Medications

Adding bevacizumab improves overall survival in NSCLC

(HealthDay)—The addition of bevacizumab to carboplatin/pemetrexed is associated with improved overall survival among patients with advanced non-small cell lung cancer (NSCLC), according to a study published in the May issue ...

Oncology & Cancer

Many older patients with AML not receiving active treatment

(HealthDay)—Many older patients with acute myeloid leukemia (AML) do not receive any active treatment, and they have worse survival than those receiving active treatment, according to a study published online Sept. 4 in ...

Oncology & Cancer

High response seen for chemo in seniors with high-risk AML

(HealthDay)—A substantial proportion of older patients with high-risk acute myeloid leukemia (AML) treated with chemotherapy are long-term survivors, according to research published online June 7 in Cancer Medicine.